Journal article
Azacitidine in adult patients with acute myeloid leukemia
AC Schuh, H Döhner, L Pleyer, JF Seymour, P Fenaux, H Dombret
Critical Reviews in Oncology Hematology | ELSEVIER SCIENCE INC | Published : 2017
Abstract
Azacitidine is recommended front-line treatment for older patients with acute myeloid leukemia (AML) who are not candidates for intensive treatment regimens, and was recently granted approval in the European Union for treatment of adult AML. Reviewed here is azacitidine experience in AML, including: mechanistic and pharmacokinetic data; safety and efficacy in controlled trials; treatment effects in AML subpopulations defined by disease characteristics; experience in unselected patients treated in the community setting; clinical outcomes relative to other approved AML therapies; and experience with azacitidine-based combination treatment regimens. Collectively, these data suggest that (a) aza..
View full abstractGrants
Funding Acknowledgements
All authors equally contributed to, revised, and approved manuscript content, and approved submission to the journal. The authors received editorial support during manuscript development from Sheila Truten and Kelly Dittmore of MC2 Inc., Wynnewood, PA, who were funded by Celgene Corporation. Celgene did not contribute to content or participate in the development of this paper. The authors are fully responsible for all content and editorial decisions.